Mesoblast Limited

Mesoblast Limited is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The stock has a good momentum. Mesoblast Limited is not a good value stock. Mesoblast Limited is not very popular among insiders. Mesoblast Limited is a mediocre stock to choose.
Log in to see more information.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and marke...
MESO Fundamental Data by TradingView

News

Mesoblast (NASDAQ:MESO) Shares Pass Below 50 Day Moving Average of $6.80
Mesoblast (NASDAQ:MESO) Shares Pass Below 50 Day Moving Average of $6.80

Zolmax Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.80 and traded...\n more…

Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com to "Sell"
Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com to "Sell"

Zolmax StockNews.com cut shares of Mesoblast (NASDAQ:MESO - Free Report) from a hold rating to a sell rating in a report issued on Wednesday.\nSeveral other equities analysts have also recently weighed in on...\n more…

Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com to Sell
Mesoblast (NASDAQ:MESO) Downgraded by StockNews.com to Sell

Ticker Report Mesoblast (NASDAQ:MESO - Get Free Report) was downgraded by stock analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Wednesday. A number of other analysts...\n more…

Mesoblast (NASDAQ:MESO) Rating Reiterated by Cantor Fitzgerald
Mesoblast (NASDAQ:MESO) Rating Reiterated by Cantor Fitzgerald

Zolmax Mesoblast (NASDAQ:MESO - Get Free Report)s stock had its "overweight" rating reaffirmed by equities researchers at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga...\n more…

Mesoblast (NASDAQ:MESO) Upgraded by Jefferies Financial Group to "Buy"
Mesoblast (NASDAQ:MESO) Upgraded by Jefferies Financial Group to "Buy"

Ticker Report Jefferies Financial Group upgraded shares of Mesoblast (NASDAQ:MESO - Free Report) from a hold rating to a buy rating in a report issued on Thursday, MarketBeat Ratings reports. A number of other...\n more…

Mesoblast just upgraded at Jefferies, here's why
Mesoblast just upgraded at Jefferies, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…